Trinity Biotech (NASDAQ:TRIB – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, April 3rd. Analysts expect the company to announce earnings of ...

Trinity Biotech projects an annualized run rate of $20 million in EBITDASO and $75 million in revenues by Q2 2025, with a 20% sales increase and a $6.5 million EBITDA turnaround anticipated in 2025.

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, announced it has secured an additional $4 million in debt financing from Perceptive Advisors.

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech received Nasdaq notices for non-compliance with bid price and market value requirements, with 180 days to address deficiencies. Trinity Biotech plc, a biotechnology company ...

EDT Trinity Biotech (TRIB) files to sell 4.29M American Depositary Shares for holdersLight Up your Portfolio with Spark:Easily identify ...

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the ...

DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management ...

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...